PhD

Dr. Cheng-Lung Ku is the co-founder of Elixiron, currently serving as the company's Chief Scientific Officer and Director. Dr. Ku holds a Ph.D. in Immunology from the University of Paris V and is currently a Distinguished Professor at Chang Gung University's Clinical Medicine Research Institute, as well as the Director of the Molecular and Clinical Immunology Center. He also holds joint research positions in the Pediatrics and Nephrology departments at Chang Gung Memorial Hospital. His research interests primarily focus on translational studies of human immune-related diseases, including genetic immunodeficiency and anti-cytokine autoantibodies. By combining clinical translational research with advanced biological research techniques, he explores the pathogenic mechanisms of these diseases.

Dr. Ku's primary research focus is on anti-interferon-gamma autoantibodies. He has made significant advancements in identifying the genetic factors, clinical symptoms, and antibody-inducing mechanisms associated with this condition. Utilizing single B cell cloning technology, Dr. Ku isolates these antibodies to investigate their biochemical properties and pathogenic mechanisms in depth. A notable achievement in his work is the cloning of the anti-interferon-gamma autoantibody, which has been transferred to Elixiron for drug development (Indemakitug, EI-001). Dr. Ku is currently actively involved in the clinical development of this promising therapeutic.

Dr. Ku's research performance is exceptional, with numerous research achievements published in top international scientific journals such as Nature Medicine, Science, Journal of Experimental Medicine, Science Immunology, and Blood. Due to his outstanding research achievements, he has received several academic awards, including the Academia Sinica Young Scholar's Paper Award, the Ta-You Wu Memorial Award, the Ministry of Science and Technology Outstanding Research Award, and the Ministry of Science and Technology Outstanding Technology Transfer Award.